Jonathan Hernandez, M.D.
Cholangiocarcinoma (CCA) is an aggressive cancer of the bile ducts that connect the liver, gallbladder and small intestines. A clinical trial led by Jonathan M. Hernandez, M.D., Investigator in the Surgical Oncology Program, is researching targeted drug therapy for CCA and gallbladder cancer.
The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for participation.
For more information, contact Kate Smith at (240) 858-3531 or kathleen.smith3@nih.gov.
Clinicaltrials.gov identifier: NCT04645160
NCI Protocol ID: 21-C-0006
Official Title: Phase II Study Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.
For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.